(Colorado Newsline) Democratic leaders, health care providers and consumer advocates praised a Colorado board’s decision last ...

Last year, the board voted to deem Enbrel “unaffordable,” setting up a months-long process of determining whether it should ...

Colorado became the first state in the nation to set a price cap on a specific medication last week, following a unanimous ...

Medicare was authorized to negotiate prices it will pay for Part D drugs. Enbrel, the original version of etanercept, was among the first 10 drugs to be subject to negotiations. The negotiated price ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a biosimilar product in the United States to compete with Amgen's blockbuster Enbrel ...

The Colorado Prescription Drug Affordability Review Board imposed a first-in-the-nation price cap on the drug Enbrel, starting in 2017.

A Colorado panel voted Friday to cap the price for a best-selling drug from Amgen. It is one of four states that have passed ...

Alston & Bird represent plaintiff Sandoz Inc. in an antitrust lawsuit against Amgen. Munger, Tolles & Olson and Kaufman & Canoles represent Amgen in a related case in the Eastern District of Virginia.

In a first-in-the-nation move, a Colorado panel voted to limit what health plans in the state will pay for a costly arthritis ...

Upper payment limits (UPL) present clear challenges and dangers to patients because of its potential impact on access to life ...

AbbVie is on the rebound after a sell-off on concerns about the pending FDA decision for a biosimilar drug. Humira and Enbrel are among the top-selling drugs to be copycatted but biosimilars are ...